DUBLIN--(BUSINESS WIRE)--The "Acute Decompensated Heart Failure Forecast and Market Analysis to 2034" report has been added to ResearchAndMarkets.com's offering.
Acute decompensated heart failure (ADHF) is defined as the sudden worsening of heart failure symptoms (mainly edema, dyspnea, and fatigue), which results in severe respiratory distress. ADHF is categorized into hemodynamic stages based on the degree of perfusion and pulmonary capillary wedge pressure. Despite improvements in treatment, ADHF is a burdensome disease associated with high hospitalization and mortality rates in the elderly population.
Recent events and opinion
- Recent pipeline discontinuations and negative trial results have limited the future growth of the ADHF market.
- ADHF treatment is focused on hemodynamic stabilization and alleviation of symptoms.
- The author estimates that in 2016, there were 1.2 million diagnosed incident cases of ADHF in the US, Japan, and five major EU markets.
- Negative results of the LEVO-CTS trial will prevent expansion of Simdax into the low cardiac output syndrome market.
- The discontinuations of ularitide and Reasanz dramatically reduce the number of agents in development for ADHF.
Key Topics Covered:
Forecast: Acute Decompensated Heart Failure
Treatment: Acute Decompensated Heart Failure
- Primary Research Methodology
- Disease Definition And Diagnosis
- Current Treatment Options
- Prescribing Trends
Epidemiology: Acute Decompensated Heart Failure
- Disease Background
- Sources And Methodology
- Epidemiologist Insight
- Strengths And Limitations
- Appendix: Additional Sources
Marketed Drugs: Acute Decompensated Heart Failure
- Product Overview
- Product Profile: Natrecor
- Product Profile: Simdax
Pipeline: Acute Decompensated Heart Failure
- Recently Discontinued Drugs
For more information about this report visit https://www.researchandmarkets.com/research/vh4r4d/global_acute?w=4